Trinity Biotech (TRIB) EBT Margin (2009 - 2024)
Trinity Biotech (TRIB) posted quarterly EBT Margin of 99.62% for Q4 2024, down 5863.0% year-on-year from 1.73% in Q1 2024, and down 214.87% on a QoQ basis from 31.64% in Q3 2024.
Trinity Biotech (TRIB) EBT Margin (2009 - 2024) Analysis & Trends
Trinity Biotech (TRIB) has reported EBT Margin for 16 consecutive years, with 99.62% the latest figure, recorded in Q4 2024.
- Quarterly EBT Margin fell 5863.0% year-over-year to 99.62% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 49.92% (up 1506.0% YoY) and the FY2025 annual result came in at 84.91%, down 3499.0% from the prior year.
- EBT Margin eased to 99.62% in Q4 2024 per TRIB's latest filing, from 31.64% in the prior quarter.
- Over the last five years, EBT Margin for TRIB reached as high as 24.59% in Q3 2020 and fell as low as 133.93% in Q2 2023.
- A 5-year average of 36.09% and a median of 41.79% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2020 — EBT Margin jumped 9961 bps — and 2022, when it sank 10110 bps.
- Year by year, EBT Margin stood at 43.59% in 2020, then soared by 71 bps to 12.44% in 2021, then plunged by 433 bps to 66.32% in 2022, then soared by 38 bps to 41.0% in 2023, then tumbled by 143 bps to 99.62% in 2024.
- According to Business Quant data, EBT Margin over the past three periods registered 99.62%, 31.64%, and 43.48% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Trinity Biotech | 93,750.00 | -5.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -99.62% |
| Sep 30, 2024 | -31.64% |
| Jun 30, 2024 | -43.48% |
| Mar 31, 2024 | -22.10% |
| Dec 31, 2023 | -41.00% |
| Sep 30, 2023 | -44.27% |
| Jun 30, 2023 | -133.93% |
| Mar 31, 2023 | -42.59% |
| Dec 31, 2022 | -66.32% |
| Sep 30, 2022 | -63.59% |
| Jun 30, 2022 | -65.84% |
| Mar 31, 2022 | -84.34% |
| Dec 31, 2021 | -12.44% |
| Sep 30, 2021 | 7.28% |
| Jun 30, 2021 | -0.50% |
| Mar 31, 2021 | 16.76% |
| Dec 31, 2020 | -43.59% |
| Sep 30, 2020 | 24.59% |
| Jun 30, 2020 | 10.76% |
| Mar 31, 2020 | 13.96% |